Discontinued — last reported Q1 '26
Business Segments · Other Nonoperating Income (Expense)
Pharmaceutical — Other Nonoperating Income (Expense)
Merck & Co. Pharmaceutical — Other Nonoperating Income (Expense) decreased by 118.6% to -$55.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.2%, from -$49.00M to -$55.00M. Over 3 years (FY 2022 to FY 2025), Pharmaceutical — Other Nonoperating Income (Expense) shows an upward trend with a 448.5% CAGR.
Analysis
StatementSegment
CategoryOther
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026
How to read this metric
Significant non-operating income can artificially inflate segment profitability, while expenses can mask strong operational performance.
Detailed definition
Financial gains or losses that are not related to the core pharmaceutical operations, such as interest income, foreign e...
Peer comparison
Commonly reported across all sectors; investors typically strip these out to analyze core operating margins.
Metric ID:
mrk_segment_pharmaceutical_segment_other_nonoperating_income_expenseHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$250.00K | -$250.00K | -$250.00K | -$250.00K | $12.25M | $12.25M | $12.25M | $12.25M | -$33.00M | -$14.00M | -$27.00M | $163.00M | -$49.00M | -$21.00M | -$60.00M | $295.00M | -$55.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | >999% | +0.0% | +0.0% | +0.0% | -369.4% | +57.6% | -92.9% | +703.7% | -130.1% | +57.1% | -185.7% | +591.7% | -118.6% |
| YoY Change | — | — | — | — | >999% | >999% | >999% | >999% | -369.4% | -214.3% | -320.4% | >999% | -48.5% | -50.0% | -122.2% | +81.0% | -12.2% |
Range-$60.00M – $295.00M
CAGR+285.1%
Avg YoY Growth>999%
Median YoY Growth-12.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s pharmaceutical — other nonoperating income (expense)?
- Merck & Co. (MRK) reported pharmaceutical — other nonoperating income (expense) of -$55.00M in Q1 2026.
- How has Merck & Co.'s pharmaceutical — other nonoperating income (expense) changed year-over-year?
- Merck & Co.'s pharmaceutical — other nonoperating income (expense) decreased by 12.2% year-over-year, from -$49.00M to -$55.00M.
- What is the long-term trend for Merck & Co.'s pharmaceutical — other nonoperating income (expense)?
- Over 3 years (2022 to 2025), Merck & Co.'s pharmaceutical — other nonoperating income (expense) has grown at a 448.5% compound annual growth rate (CAGR), from -$1.00M to $165.00M.
- What does pharmaceutical — other nonoperating income (expense) mean?
- Non-core financial gains or losses outside of regular pharmaceutical operations.